Trials / Terminated
TerminatedNCT01046097
Post-marketing Surveillance Study With GSK Biologicals' Pneumococcal Vaccine in Healthy Infants in Philippines
Post-marketing Surveillance Study of GSK Biologicals' Pneumococcal Conjugate Vaccine, Synflorix, When Administered According to the Local Prescribing Information in Philippines
- Status
- Terminated
- Phase
- —
- Study type
- Observational
- Enrollment
- 28 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 6 Weeks – 5 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this post-marketing surveillance study is to evaluate the safety of Synflorix™ when administered according to the local Prescribing Information to healthy Filipino infants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Synflorix™ | Intramuscular administration of three doses/two doses/one dose of primary vaccination/the booster dose/ catch-up dose(s) of Synflorix according to local prescribing information. |
Timeline
- Start date
- 2010-05-01
- Primary completion
- 2013-07-01
- Completion
- 2013-07-01
- First posted
- 2010-01-11
- Last updated
- 2016-05-16
Locations
2 sites across 1 country: Philippines
Source: ClinicalTrials.gov record NCT01046097. Inclusion in this directory is not an endorsement.